Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as formidable players in the global drug development landscape, securing…
Read More

Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as formidable players in the global drug development landscape, securing…
Read More
The advent of accessible home testing kits is significantly transforming the landscape of bowel cancer screening, making it more convenient…
Read More
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
The pharmaceutical industry is experiencing a significant transformation as artificial intelligence (AI) tools move beyond experimental phases to deliver tangible…
Read More
Novartis has achieved significant regulatory successes on two fronts, with its oral therapy Rhapsido (remibrutinib) receiving marketing authorisation from the…
Read More
Eli Lilly and Company has officially concluded its fiscal year 2025 as the world’s leading pharmaceutical enterprise by revenue, a…
Read More
Canadian pharmaceutical giant Apotex has announced a significant strategic acquisition, agreeing to purchase Cumberland Pharmaceuticals’ entire portfolio of branded commercial…
Read More
Regeneron Pharmaceuticals has entered into a significant drug pricing agreement with the White House, marking a pivotal moment in the…
Read More
Clinical trials in the highly complex and rapidly evolving field of cardiometabolic disease face a critical juncture: their success or…
Read More
The pharmaceutical industry’s financial landscape is undergoing a significant transformation, marked by the continued brand dominance of Merck’s Keytruda (pembrolizumab)…
Read More